Jordan Stanley C, Vo Ashley, Tyan Dolly, Toyota Mieko
Comprehensive Transplant Center, Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90048, USA.
Trans Am Clin Climatol Assoc. 2006;117:199-211; discussion 211.
Intravenous immunoglobulin products (IVIG) are derived from pooled human plasma and have been used for the treatment of primary immunodeficiency disorders for more than 24 years. Shortly after their introduction, IVIG products were found to be effective in the treatment of autoimmune and inflammatory disorders. Over the past 2 decades, the list of diseases where IVIG has a demonstrable beneficial effect has grown rapidly. These include inflammatory diseases such as Kawasaki disease, Guillain-Barre syndrome, myasthenia gravis, dermatomyositis and demyelinating polyneuropathy. Recently, we have described a beneficial effect on the reduction of anti-HLA antibodies with subsequent improvement in rates of transplantation for highly human leukocyte antigen (HLA) sensitized patients as well as a potent anti-inflammatory effect that is beneficial in the treatment of antibody-mediated rejection (AMR). These advancements have enabled transplantation of patients previously considered untransplantable and in concert with new diagnostic techniques has resulted in new approaches to management of AMR.
静脉注射免疫球蛋白产品（IVIG）源自混合人血浆，已用于治疗原发性免疫缺陷疾病超过24年。在引入后不久，IVIG产品被发现对自身免疫性和炎症性疾病有效。在过去20年中，IVIG具有明显有益作用的疾病清单迅速增加。这些疾病包括炎症性疾病，如川崎病、格林-巴利综合征、重症肌无力、皮肌炎和脱髓鞘性多发性神经病。最近，我们描述了其对减少抗HLA抗体的有益作用，随后提高了高度人类白细胞抗原（HLA）致敏患者的移植率，以及对治疗抗体介导的排斥反应（AMR）有益的强大抗炎作用。这些进展使以前被认为无法移植的患者能够进行移植，并且与新的诊断技术相结合，产生了AMR管理的新方法。
